1471. Treatment of Influenza with Baloxavir was Associated with Reduced Absenteeism Compared with Oseltamivir in a Patient-Generated Health Data Study


 
 
 Lost productivity from workplace absenteeism is a significant component of the economic burden of influenza [1]. Antiviral treatment together with influenza vaccination may help reduce work time lost from influenza illness [2]. In clinical trials, baloxavir, an oral single dose treatment for influenza, demonstrated comparable symptom resolution to oseltamivir taken twice daily for 5 days [3]. We examined baloxavir real-world outcomes using patient generated health data (PGHD) to investigate the association between antiviral use and workplace absenteeism.
 
 
 
 Using data from a participatory influenza-like illness (ILI) surveillance program (ISP), we identified participants who self-reported ILI using the online Evidation platform during the 2019-2020 influenza season in the United States. Participants who self-reported treatment with baloxavir or oseltamivir were included. We conducted an ordinal logistic regression to estimate the odds of missing work due to ILI, while adjusting for use of over-the-counter (OTC) medication, age, number of symptoms, US region, and comorbidities.
 
 
 
 Of 3658 participants eligible for inclusion in the analysis, 3285 (89.8%) were prescribed oseltamivir and 373 (10.2%) were prescribed baloxavir. A majority of participants (81.7%) reported missing at least one day of work. In the ordinal logistic regression, use of baloxavir was associated with lower odds of absenteeism, compared to oseltamivir (odds ratio [OR]: 0.748, 95% confidence interval [CI]: 0.616, 0.907). In addition, a higher number of symptoms (OR 2.922, 95% CI: 2.454, 3.481), older age (OR: 1.425, 95% CI: 1.162, 1.747), and use of OTC medication (OR: 1.242, 95% CI: 1.086, 1.420) were associated with higher odds of absenteeism. Due to a high rate of missing data on the timing of antiviral use (24.5% missing), its association with absenteeism could not be adequately assessed.
 
 
 
 Treatment of patients with ILI with single dose baloxavir was associated with reduced workplace absenteeism compared to oseltamivir after adjusting for measured confounders. This study provides useful insight into factors associated with ILI-related workplace absenteeism and the potential real-world utility of baloxavir.
 
 
 
 Hao Xu, MSc, Hoffmann-La Roche Limited: Employee Vincent Ukachukwu, n/a, Roche Products Ltd: Employee Devika Chawla, PhD, Genentech: Employee.
